1. Generics Bulletin
  2. >>Products
  3. >>Generics

Zydus Knocked Back On Farxiga In US As Brand Continues To Grow

US Court Finds Key Patent Is Not Invalid As Obvious

 
• By Dean Rudge

Zydus Cadila has failed to prove to a US court that a US patent expiring in October 2025 that shields AstraZeneca’s Farxiga (dapagliflozin) SGLT2 inhibitor is obvious, keeping the firm’s proposed ANDA product off of the market for now.

patents
Zydus failed to have a key US Farxiga patent invalidated • Source: Alamy

Key claims of a US patent shielding AstraZeneca’s Farxiga (dapagliflozin) tablets to treat diabetes are not invalid, a US district court has ordered, handing a setback to abbreviated new drug application sponsor Zydus Cadila.

Following trial in May this year, Delaware district judge Richard Andrews concluded that five claims of US patent 6,515,117 – which is to expire October

More from Generics

More from Products